Ultimovacs ASA (Norway) Today
| ULTI Stock | NOK 2.07 0.02 0.98% |
Performance0 of 100
| Odds Of DistressOver 65
|
Ultimovacs ASA is selling for 2.07 as of the 27th of November 2024. This is a 0.98% up since the beginning of the trading day. The stock's lowest day price was 2.04. Ultimovacs ASA has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Ultimovacs ASA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway. The company has 34.4 M outstanding shares. More on Ultimovacs ASA
Moving against Ultimovacs Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Ultimovacs Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ultimovacs ASA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ultimovacs ASA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Ultimovacs ASA (ULTI) is traded on Oslo Stock Exchange in Norway and employs 23 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.11 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ultimovacs ASA's market, we take the total number of its shares issued and multiply it by Ultimovacs ASA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ultimovacs ASA operates under Healthcare sector and is part of Biotechnology industry. The entity has 34.4 M outstanding shares.
Ultimovacs ASA has accumulated about 1.85 M in cash with (125.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ultimovacs ASA Probability Of Bankruptcy
Ownership AllocationUltimovacs ASA shows a total of 34.4 Million outstanding shares. Ultimovacs ASA maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ultimovacs Ownership Details
Ultimovacs ASA Risk Profiles
Although Ultimovacs ASA's alpha and beta are two of the key measurements used to evaluate Ultimovacs ASA's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.68 | |||
| Standard Deviation | 6.62 | |||
| Variance | 43.87 | |||
| Risk Adjusted Performance | (0.01) |
Ultimovacs Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ultimovacs ASA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Ultimovacs ASA Corporate Management
Elected by the shareholders, the Ultimovacs ASA's board of directors comprises two types of representatives: Ultimovacs ASA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ultimovacs. The board's role is to monitor Ultimovacs ASA's management team and ensure that shareholders' interests are well served. Ultimovacs ASA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ultimovacs ASA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antonius Berkien | Chief Officer | Profile | |
| Pr Gaudernack | Chief Officer | Profile | |
| Hans Eid | Chief Officer | Profile | |
| Audun Tornes | Chief Officer | Profile | |
| Gudrun Troite | Head Coordination | Profile | |
| Anne Worsoe | Head Communication | Profile | |
| Oivind Foss | Head Operations | Profile |
Other Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.